|
0
|
|
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.
(linkinghub.elsevier.com)
|
Dawson R
…
Hafkin J
Lancet Infectious Diseases
2026-05-29
|
#amr
#clinical trial
#drug therapy
#tb
|
|
0
|
|
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.
(academic.oup.com)
|
Diamond TL
…
Asante-Appiah E
Journal of Infectious Diseases
2026-05-29
|
#amr
#clinical trial
#hiv
#viral_suppression
|
|
0
|
|
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
(linkinghub.elsevier.com)
|
Xiong A
…
Zhou C
The Lancet
2026-05-29
|
#cancer
#clinical trial
#immunotherapy
#lung cancer
#pd-l1
|
|
0
|
|
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
(nejm.org)
|
Zhou C
…
Heymach JV
New England Journal of Medicine
2026-05-29
|
#clinical trial
#mutation
#nsclc
#targeted therapy
#egfr
|
|
0
|
|
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
(nejm.org)
|
Touzeau C
…
Landgren O
New England Journal of Medicine
2026-05-29
|
#antibody
#cancer
#clinical trial
#immunotherapy
|